"10.1371_journal.pone.0104230","plos one","2014-08-11T00:00:00Z","Marjolein Sluijter; Tetje C van der Sluis; Pieter A van der Velden; Mieke Versluis; Brian L West; Sjoerd H van der Burg; Thorbald van Hall","Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, the Netherlands; Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands; Plexxikon Inc., Berkeley, California, United States of America","Conceived and designed the experiments: SVDB TVH. Performed the experiments: MS MV TVDS. Analyzed the data: TVDS MS. Contributed reagents/materials/analysis tools: BW PVDV. Contributed to the writing of the manuscript: TVH.","Co-author Thorbald van Hall is a PLOS ONE Editorial Board member. Brian L. West is employed by a commercial company Plexxikon Inc. and supplied the PLX3397 kinase inhibitor for free. Plexxikon Inc. holds the following patents on this compound: 20130178473 Compounds modulating c-fms and/or c-kit activity and uses therefor; 20120309756 Compounds modulating c-fms and/or c-kit activity and uses therefor; 20110230482 Compounds modulating c-fms and/or c-kit activity; 20110166174 Compounds modulating c-kit and c-fms activity and uses therefor; 20090076046 Compounds modulating c-fms and/or c-kit activity and uses therefor; and is currently involved in clinical trials testing this drug. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","08","Marjolein Sluijter","MS",7,TRUE,2,3,2,NA,TRUE,TRUE,FALSE,0,NA,FALSE
